Evidence map›Paper›PMID 34429783›Full record

ArticleJournal of smoking cessation2021

An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders.

Nicholas J K Breitborde, Brittney Keller-Hamilton, Aubrey M Moe, Jacob G Pine, Nicholas Nelson, David Weiss, Tory Hogan, Amanda Quisenberry, Andreas Teferra, Amy K Ferketich

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of smoking cessation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nicholas J K BreitbordeThe Ohio State University, USA.ORCID https://orcid.org/0000-0002-9877-3719
Brittney Keller-HamiltonThe Ohio State University, USA.ORCID https://orcid.org/0000-0002-8574-7263
Aubrey M MoeThe Ohio State University, USA.
Jacob G PineThe Ohio State University, USA.ORCID https://orcid.org/0000-0002-1814-5887
Nicholas NelsonSoutheast, Inc., USA.ORCID https://orcid.org/0000-0002-9425-6263
David WeissThe Ohio State University, USA.ORCID https://orcid.org/0000-0001-5806-4144
Tory HoganThe Ohio State University, USA.ORCID https://orcid.org/0000-0001-8403-9735
Amanda QuisenberryRoswell Park Comprehensive Cancer Center, USA.ORCID https://orcid.org/0000-0003-0108-8473
Andreas TeferraThe Ohio State University, USA.ORCID https://orcid.org/0000-0002-8052-6605
Amy K FerketichThe Ohio State University, USA.ORCID https://orcid.org/0000-0001-8390-8679
The Ohio State University · USRoswell Park Comprehensive Cancer Center · USSoutheast University · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIndividuals with psychotic-spectrum disorders may smoke due to the ameliorating effect of nicotine on the cognitive deficits that accompany these illnesses. Metacognitive remediation therapy (MCR) has been shown to produce improvements in cognitive functioning among individuals with psychotic-spectrum disorders and provides a foundation for a novel smoking cessation intervention for this population.

aimsTo complete an open investigation of pharmacotherapy and a modified version of MCR [MCR to Quit (MCR-Q)] in promoting smoking cessation among individuals with psychotic-spectrum disorders.

methodsForty-nine individuals with a psychotic-spectrum disorder and who currently smoke cigarettes participated in MCR-Q while also receiving evidence-based smoking cessation pharmacotherapy. Tobacco use was assessed as follows: (i) prior to MCR-Q, (ii) immediately after completing MCR-Q, and (iii) six weeks after completion of MCR-Q.

results/

conclusionsThe results from the current study suggest cautious optimism with regard to the use of MCR-Q in combination with medication for individuals with psychotic-spectrum disorders who want to quit smoking.

Identifiers

PMID34429783
PMCPMC8337155
OpenAlexW3184350172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.